BioCentury | Jan 27, 2017
Targets & Mechanisms

Death metal

...LSE:GSK; NYSE:GSK). Nexavar is marketed by Amgen Inc. (NASDAQ:AMGN) and Bayer AG (Xetra:BAYN). ACSL4 - Acyl-CoA synthetase long-chain family member 4...
...Table: BIOCENTURY PRODUCT PROFILE BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Small molecule ACSL4 inhibitor Concept ACSL4...
...Basel, Switzerland Technische Universität Dresden, Dresden, Germany University of Antwerp, Antwerp, Belgium Targets ACSL4 - Acyl-CoA synthetase long-chain family member 4...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Renal disease

...INDICATION: Renal failure Mouse studies suggest inhibiting ACSL4 could help treat acute renal failure. In a...
...cell death mechanism associated with acute renal failure, ACSL4 knockout increased viability compared with normal ACSL4...
...also inhibits ACSL4, increased survival compared with vehicle. Next steps include developing specific inhibitors of ACSL4...
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV Acyl-CoA synthetase long-chain family member 1 (ACSL1) Cell culture studies suggest inhibiting synthesis of triacylglycerides and cholesterol esters by ACSL1 could help treat...
BioCentury | Apr 15, 2013
Company News

MGA Software Inc., Millard Fillmore Healthcare System deal

MGA will provide Fillmore with its ACSL BioMed clinical trial simulation software for an undisclosed fee. Fillmore, a teaching hospital for the State University of New York at Buffalo, will use the software to train...
BioCentury | Apr 15, 2013
Company News

MGA Software Inc. sales and marketing update

MGA began selling ACSL BioMed 2.1 clinical trial simulator software targeted to pharmacologists. ACSL BioMed helps design, pre-test and modify study parameters prior to conducting live trials, MGA said. The cost is $20,000. MGA Software...
BioCentury | Jan 26, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Acyl-CoA synthetase long-chain family member 1 (ACSL1) Studies in mice and in patient samples suggest inhibiting ACSL1 could help...
BioCentury | Dec 15, 1997
Company News

MGA Software Inc. sales and marketing update

MGA launched its ACSL BioMed 3.1 computer-assisted clinical trial design software. The system allows simulation of trials in specific patient populations. MGA Software Inc., Concord, Mass. Business: Enabling technology WIR Staff...
BioCentury | Feb 24, 1997
Company News

MGA Software Inc. sales and marketing update

MGA launched ACSL BioMed, which it said is the first commercially available PC software for simulating clinical drug trials. The program, priced at $20,000, allows researchers to design, pre-test and modify study parameters before conducting...
Items per page:
1 - 8 of 8